Teaching an old dog new tricks: re-engineering IL-2 for immuno-oncology applications
Journal for ImmunoTherapy of Cancer · 2023
DOI: 10.1136/jitc-2022-006346 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2023. Verfasst von Mario Sznol und 1 weiteren Autor:innen. Beteiligte Einrichtung: Yale Cancer Center, Yale University, New Haven, Connecticut, USA mario.sznol@yale.edu. Hauptthemen laut MEDLINE: Melanoma, Kidney Neoplasms. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCATS NIH HHS.
Abstract (Originalsprache)
Various approaches are being explored to address the unmet medical need among patients with advanced cancer who do not respond to immune checkpoint inhibitors. Interleukin-2 has become a prominent focus of preclinical and clinical investigation, because of its known clinical activity, the important role of this cytokine in immune biology, and the ability to engineer variant proteins with potentially improved antitumor immunomodulatory activity and reduced toxicity. Bempegaldesleukin, the first of the modified IL-2 agents to reach phase 3 evaluation in combination with an anti-PD-1, did not improve outcome for patients with metastatic melanoma and renal carcinoma. The disappointing data raise important questions about the potential efficacy of other interleukin-2 variants, however, several of the other variants appear to be sufficiently differentiated in anticipated pharmacokinetic properties and immune modulatory effects to warrant continued clinical development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Yale Cancer Center, Yale University, New Haven, Connecticut, USA mario.sznol@yale.edu.
- Synthekine, Menlo Park, California, USA.
ORCID-Profile: Mario Sznol
Förderung
- NCATS NIH HHS
Zitieren
APA
Sznol, M., & Rizvi, N. (2023). Teaching an old dog new tricks: re-engineering IL-2 for immuno-oncology applications. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2022-006346
Vancouver
Sznol M, Rizvi N. Teaching an old dog new tricks: re-engineering IL-2 for immuno-oncology applications. Journal for ImmunoTherapy of Cancer. 2023. doi:10.1136/jitc-2022-006346
BibTeX
@article{Sznol2023,
author = {Sznol, Mario and Rizvi, Naiyer},
title = {Teaching an old dog new tricks: re-engineering IL-2 for immuno-oncology applications},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2023},
doi = {10.1136/jitc-2022-006346}
}
EUVIMED